Previous close | 0.6404 |
Open | 0.6452 |
Bid | 0.6293 x 100 |
Ask | 0.6654 x 300 |
Day's range | 0.6210 - 0.6518 |
52-week range | 0.2450 - 4.0380 |
Volume | |
Avg. volume | 1,853,077 |
Market cap | 49.104M |
Beta (5Y monthly) | 1.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.9000 |
Earnings date | 15 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.00 |
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas